Locations
Japan
Next Generation Site Identification from Theory to Practice
Global Site
Locations
Americas
Argentina
Brasil
Canada
Canada (English)
Canada (Français)
Colombia
Mexico
Mexico (English)
México (Español)
United States
Europe, Middle East & Africa
Adriatic
Belgium
Belgium (English)
Belgique (Français)
België (Nederlands)
Bulgaria
Bulgaria (English)
България (Български)
Czech Republic
Czech Republic (English)
Czech Republic (Česky)
Denmark
España
Finland
France
Deutschland
Greece
Greece (English)
Ελλάδα (Ελληνικά)
Hungary
Ireland
Israel
Italy
Italy (English)
Italia (Italiano)
Middle East and Africa
Nederland
Nordics
Norway
Poland
Portugal
Portugal (English)
Portugal (Português)
Romania
Romania (English)
Romania (Română)
Russia
Russia (English)
Россия и СНГ (Русский)
Slovakia
Slovakia (English)
Slovakia (Slovensky)
Sweden
Switzerland
Switzerland (English)
Switzerland (Deutsch)
Turkey
Turkey (English)
Türkiye (Türkçe)
Ukraine
Ukraine (English)
Україна (Українська)
United Kingdom
Asia
Asia Pacific
Australia and NZ
中国
India
Indonesia
Japan
대한민국
Malaysia
Pakistan
Philippines
Singapore
Sri Lanka
Thailand
Vietnam
Japan Menu
ソリューション
CRO事業
概要
オンコロジー領域製品開発
中枢神経領域製品開発
各種疾患領域製品開発
再生医療等製品開発
医療機器開発
開発戦略・薬事コンサルティング
臨床試験
バーチャル臨床試験
グローバルラボラトリー
Clinical Development in Japan
Overview
リアルワールド インサイト
概要
リアルワールドデータ コンサルティング
Pharmacovigilance
市場データ
概要
国内データ
海外データ
コンサルティング＆サービス
概要
Management Consulting
Primary Intelligence
保険者・保険薬局向け
概要
保険者向けソリューション
保険薬局向けソリューション
テクノロジー
概要
Customer Engagement
Commercial Compliance
Quality Compliance
CSO事業
概要
CSO事業 のアプローチ
IQVIA Remote Detailing
業界トレンドUPDATE
新型コロナワクチン接種計画立案支援
Thought Leadership
概要
トップライン市場データ
IQVIAジャパン について
概要
個人情報保護方針
品質・情報セキュリティ
アクセス
社会貢献活動
お知らせ
採用情報
CRO事業
CSO事業
オープンポジション検索
Menu
Solutions
Research & Development
Overview
COVID-19 Research & Development
Clinical Trials
Functional Services
Decentralized Trials
Consulting
Real World Evidence
Overview
Real World Data Sets
Healthcare Data Transformation
Study Design
Platforms
Evidence Networks
Health Economics & Value
Regulatory and Safety
Commercialization
Overview
COVID-19 Commercialization
Launch Strategy and Management
Brand Strategy and Management
Pricing and Market Access
Healthcare Professional Engagement
Patient Engagement
Promotional Strategy
Integrated Global Compliance
Safety Pharmacovigilance
Regulatory Compliance
Quality Compliance
Medical Information
Commercial Compliance
Technologies
Overview
Orchestrated Clinical Trials
Clinical Acceleration
Patient Engagement
Content Management
Customer Engagement
Safety Regulatory & Quality
Performance Management & Insights
Information Management
Partner Programs
Industry Segments
Overview
Pharmaceutical Manufacturers
Emerging Biopharma
Consumer Health
MedTech
Generics
Information Partner Services
Financial Institutions
Public Health and Government
Patient Associations
Payers
Providers
Featured Capabilities
Human Data Science Cloud
Innovative Models
Virtual Research
Genomics
Digital Health
Therapeutic Areas
Oncology
Rare Diseases
GI and Hepatology
Diabetes
Pediatrics
Cardiovascular
Biosimilars
COVID-19 Resources
Insights
IQVIA Insights
Blogs, White Papers, Case Studies
IQVIA Institute
About
Our Story
Human Data Science
IQVIA Connected Intelligence
Executive Team
Contact
Locations
Investors
News
Events and Webinars
Privacy
Careers
Working at IQVIA
Life at IQVIA
See all jobs
Locations
Japan
Next Generation Site Identification from Theory to Practice
次世代の施設選定 理論から実践へ
出版物
Dec 10, 2018
Download
Share
IQVIA米国本社発行レポート「Next Generation Site Identification from Theory to Practice」の日本語版です。
You may also be interested in
You are about to exit for another IQVIA country or region specific website
Please be aware that the website you have requested is intended for the residents of particular country or region, as noted on that site.
OK
Open in a new tab
For this browsing session please remember my choice and don't ask again.
お問い合わせ CONTACT US
お問い合わせ CONTACT US
メール EMAIL US
こちらから SEND EMAIL
